-
Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age?W Sumaya, RF Storey. -
Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin?KM Ziada; DJ Moliterno et al.
-
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trialJ Silvain, B Lattuca, ALPHEUS investigators et al.
-
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS TrialFox KAA, Eikelboom JW, Yusuf S et al.
-
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journeyD Cao, R Chandiramani, M Chiarito et al.
-
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding RiskM Valgimigli, E Frigoli, the MASTER DAPT Investigators et al.
-
Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and ThrombolysisZQ Zhao, XB Zhang, HY Zhang et al.
-
Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatmentX Zhang, XL Zhang, YL Han et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
